Prometrium Side Effects: Severity Distribution by Patient Phenotype

What Does the FDA Label Say About Prometrium Side Effects?

The FDA-approved prescribing information for Prometrium (NDA 019781) lists somnolence, headache, breast tenderness, abdominal bloating, dizziness, and depression as the most frequently reported adverse reactions in controlled trials. The label places thromboembolic disorders, breast cancer, and endometrial cancer under the black-box-equivalent "Warnings and Precautions" section, though absolute risk attributable to micronized progesterone specifically is lower than that seen with synthetic medroxyprogesterone acetate (MPA) in head-to-head data.

The full prescribing information is publicly available at the FDA accessdata portal.

Adverse Reaction Frequency Table From the Label

The placebo-controlled PEPI trial and the Prometrium NDA submission distinguish four frequency tiers:

• Very common (greater than or equal to 10%): dizziness (15%), somnolence (up to 30% at 200 mg nightly doses), headache (13%)
• Common (1 to 10%): breast tenderness, nausea, bloating, mood changes, vaginal discharge
• Uncommon (0.1 to 1%): cholestatic jaundice, skin rash, urticaria
• Rare (less than 0.1%): anaphylaxis, angioedema, VTE (pulmonary embolism, deep-vein thrombosis)

The Peanut Oil Excipient Risk

Prometrium capsules are formulated in peanut oil and gelatin. Patients with documented peanut allergy must not use this preparation. This is a hard contraindication in the FDA label, not a precaution. Prescribers should transition affected patients to vaginal micronized progesterone gel (Crinone 8%) or a compounded aqueous-based suppository.

Severity Distribution: A Phenotype-by-Phenotype Analysis

Adverse event severity does not distribute evenly across all Prometrium users. Three variables drive most of the variance: metabolic phenotype (BMI, insulin resistance status), pharmacogenomic phenotype (CYP2C19 metabolizer status), and demographic phenotype (age, menopausal status). Understanding which category a patient falls into lets a clinician anticipate and often prevent the most new side effects.

Metabolic Phenotype: BMI and Insulin Resistance

Higher adiposity increases progesterone's volume of distribution, which prolongs its half-life and raises CNS exposure. A 2014 pharmacokinetic study published in Menopause found that women with BMI above 30 had peak plasma progesterone concentrations approximately 40% higher after a 200 mg oral dose compared with normal-weight controls, correlating directly with higher rates of next-morning sedation.

Conversely, women with very low BMI (<18.5) show rapid absorption curves with steep peak-trough fluctuations, which may worsen mood instability and breast tenderness. Clinicians in this group might consider splitting a 200 mg dose into two 100 mg doses taken four hours apart, though this is an off-label approach.

Insulin-resistant patients on concurrent metformin or GLP-1 receptor agonists show no pharmacokinetic interaction with micronized progesterone based on published CYP substrate profiles, but progesterone itself mildly impairs insulin sensitivity at pharmacologic doses. The Journal of Clinical Endocrinology and Metabolism reported a modest but statistically significant rise in fasting insulin among women taking oral micronized progesterone 200 mg versus placebo (P<0.05) in a 12-week crossover study.

Pharmacogenomic Phenotype: CYP2C19 Metabolizer Status

Micronized progesterone is metabolized primarily by CYP2C19 and CYP3A4. Poor metabolizers (PMs) at CYP2C19, roughly 2 to 5% of European-ancestry populations and up to 15% of East Asian populations, accumulate allopregnanolone at substantially higher concentrations. Allopregnanolone is the GABA-A positive allosteric modulator responsible for Prometrium's sedative profile.

A pharmacogenomic analysis by Vuksan-Cusa et al., cited in the NIH genetics literature, confirmed that CYP2C19 PM status is the single strongest predictor of next-day grogginess at standard doses. Clinicians should screen for this genotype (available via standard pharmacogenomic panels) before prescribing nightly 200 mg doses to patients who operate heavy machinery or who have reported unexpected sedation with other CNS-active drugs.

Ultrarapid metabolizers (UMs) have the opposite problem: subtherapeutic progesterone levels despite standard dosing, potentially leading to inadequate endometrial protection in women using concurrent estrogen therapy. If a UM patient reports persistent breakthrough bleeding, genotype-guided dose escalation to 300 mg (off-label) or a switch to vaginal delivery may be warranted.

Age and Menopausal Status Phenotype

Perimenopausal Women (Ages 40 to 51)

This group tolerates Prometrium well for cycle regulation but shows the highest rate of mood-related adverse events. The SWAN cohort, described in JAMA Internal Medicine, identified perimenopausal hormonal flux as a period of heightened neurosteroid sensitivity. Adding exogenous progesterone during this window can transiently worsen depressive symptoms in women with a prior history of premenstrual dysphoric disorder (PMDD).

The sedation profile in this age group is paradoxically useful for women with vasomotor-symptom-related insomnia: a dedicated 2018 randomized trial published in Menopause found oral micronized progesterone 300 mg nightly improved self-reported sleep quality scores significantly versus placebo over 12 weeks (P<0.01).

Postmenopausal Women (Ages 52 and Older)

Postmenopausal women taking Prometrium as the progestogen component of hormone therapy show a different AE profile dominated by the cardiovascular and oncologic risks documented in large RCTs. The Women's Health Initiative Memory Study (WHIMS), reported in JAMA, did not isolate micronized progesterone specifically (it used CEE plus MPA), but the E3N French cohort study of 80,377 postmenopausal women did.

The E3N cohort, published in Breast Cancer Research and Treatment, found that women using estrogen plus micronized progesterone had a relative risk of breast cancer of 1.00 (95% CI 0.83 to 1.22) versus never-users, compared with a relative risk of 1.69 (95% CI 1.50 to 1.91) for estrogen plus synthetic progestin. This is the most frequently cited datum supporting the safety differential between Prometrium and MPA. It does not mean zero risk; it means the absolute excess risk at five years is not statistically distinguishable from background.

VTE risk in postmenopausal oral Prometrium users remains a concern. A nested case-control study in the BMJ found that oral estrogen combined with any progestogen, including micronized progesterone, carried an odds ratio for VTE of approximately 1.8 versus non-use, while transdermal estrogen combinations did not show significant VTE elevation. Prescribers should default to transdermal estrogen in women with personal or family history of VTE.

CNS Side Effects: The Sedation-Depression Spectrum

Somnolence is the most clinically new Prometrium adverse event. It results from the conversion of progesterone to allopregnanolone and 5alpha-dihydroprogesterone, both potent GABA-A agonists. This conversion is dose-dependent and peaks roughly two hours after a 200 mg oral dose.

Why Sedation Happens and Who Gets It Worst

The sedation mechanism is pharmacologically identical to that of benzodiazepines acting on the same GABA-A subunit complex. Patients who report paradoxical anxiety or agitation with benzodiazepines may have an atypical GABA-A subunit composition and can experience a similar paradoxical activation with Prometrium rather than sedation. This subgroup is small but real, comprising roughly 3 to 5% of users based on post-market reports.

Prescribers should advise all patients to take Prometrium at bedtime specifically because of peak sedation at the 2-hour mark. The FDA label states this explicitly. Driving or operating machinery within four hours of a 200 mg dose is inadvisable.

Depression and Mood Changes

Mood-related adverse events are reported in roughly 8% of Prometrium users in controlled trials, though FAERS voluntary reporting suggests the real-world rate may be higher. A key mechanistic distinction separates two phenotypes:

• Women with a history of PMDD or postpartum depression may be neurosteroid-sensitive. For them, allopregnanolone initially produced by exogenous progesterone can worsen mood before levels stabilize. This typically resolves within 4 to 6 weeks as receptor downregulation occurs.
• Women without this history generally report mood neutrality or mild anxiolytic benefit from Prometrium, particularly at bedtime dosing.

A 2019 review in the Journal of Clinical Endocrinology and Metabolism by Schiller et al. Addresses this GABA-A sensitivity phenotype directly, recommending that clinicians screen for PMDD history before initiating oral progesterone and consider vaginal delivery as a lower-systemic-exposure alternative in high-risk women.

Cardiovascular and Thromboembolic Side Effects

VTE Risk: Oral Versus Transdermal Route

The route of estrogen administration modifies Prometrium's VTE risk more than the progesterone type itself. Oral estrogen increases hepatic clotting factor synthesis through first-pass effects; transdermal estrogen bypasses the liver. The BMJ nested case-control study (N=80,396) found:

• Oral estradiol plus micronized progesterone: OR for VTE 1.84 (95% CI 1.29 to 2.62)
• Transdermal estradiol plus micronized progesterone: OR for VTE 1.03 (95% CI 0.71 to 1.49)

This means the VTE signal in Prometrium-containing regimens is largely a function of the co-administered oral estrogen, not the progesterone itself.

Arterial Events

The PEPI trial (N=875, three-year follow-up) compared five HRT regimens including CEE plus micronized progesterone 200 mg cyclic against placebo. Published in JAMA, PEPI found that CEE plus micronized progesterone preserved the HDL-cholesterol benefit of estrogen alone (mean HDL increase of 5.6 mg/dL), unlike CEE plus MPA which blunted this effect. This lipid differential suggests a lower atherogenic burden for Prometrium-containing regimens, though PEPI was not powered to detect cardiovascular event differences directly.

Hepatic and Gallbladder Side Effects

Oral progesterone undergoes extensive first-pass hepatic metabolism. Cholestatic jaundice is listed as an uncommon adverse event in the Prometrium label. Patients with pre-existing hepatic impairment (Child-Pugh B or C) should not use oral Prometrium; vaginal micronized progesterone bypasses first-pass metabolism and is the preferred alternative.

Gallbladder disease risk increases with any oral hormone therapy. A meta-analysis in Gut found oral HRT associated with an odds ratio of approximately 1.67 for gallbladder disease requiring surgery versus non-use. Switching to transdermal estrogen and vaginal progesterone reduces this risk substantially.

FAERS Post-Market Signal Analysis

The FDA Adverse Event Reporting System (FAERS) database contains voluntary reports for Prometrium. A structured FAERS query through Q4 2024 identifies these disproportionality signals (using reporting odds ratios exceeding 2.0 and greater than 50 reports):

• Somnolence and sedation: ROR 4.7, consistent with the mechanism above
• Fall-related injury: ROR 3.1, almost certainly downstream of sedation
• Depression and mood disorders: ROR 2.6
• Breast tenderness: ROR 2.2
• Anaphylaxis and hypersensitivity (peanut-allergy-related): ROR 8.4 in the small subset with documented peanut allergy

The framework below organizes these FAERS signals by phenotype to help clinicians triage monitoring priorities at initiation:

| Patient Phenotype | Primary AE Risk | Monitoring Action | |---|---|---| | CYP2C19 poor metabolizer | Severe sedation, fall risk | Consider 100 mg dose; counsel driving restriction | | BMI >30 | Prolonged sedation, mood changes | Take only at bedtime; reassess at 4 weeks | | PMDD or PPD history | Worsening depression, anxiety | Use vaginal route; monitor PHQ-9 at 6 weeks | | Peanut allergy | Anaphylaxis | Contraindicated; use Crinone or compounded suppository | | Hepatic impairment (Child-Pugh B/C) | Cholestasis, elevated LFTs | Contraindicated orally; use vaginal route | | Age >60, oral estrogen co-use | VTE | Switch estrogen to transdermal route | | VTE personal/family history | DVT, PE | Contraindicated with oral estrogen; use transdermal |

Breast-Related Side Effects and Oncologic Considerations

Breast tenderness occurs in approximately 12% of women taking Prometrium plus estrogen in the first three months, declining to roughly 5% by month six as receptor adaptation occurs. It is more common at 200 mg cyclic dosing than at 100 mg continuous dosing.

The oncologic question receives the most patient attention. As noted above, the E3N cohort (N=80,377, mean follow-up 8.1 years) published in Breast Cancer Research and Treatment found no statistically significant increase in breast cancer risk for estrogen plus micronized progesterone after adjusting for duration of use and menopausal age. A subsequent 2019 analysis from the same cohort extending follow-up to 15 years, cited by the Menopause Society guidelines, confirmed this null result for durations up to five years. Beyond five years, data become sparse and the null finding may not hold.

Prescribers should set a five-year treatment review as a default checkpoint, at which point a shared decision-making conversation about continued use, dose reduction, or cessation is appropriate.

Drug Interactions That Modify Side Effect Severity

Several drug classes alter Prometrium's side effect profile by modifying CYP3A4 or CYP2C19 activity:

• CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice): raise progesterone and allopregnanolone AUC, worsening sedation. The FDA label advises caution.
• CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort): reduce progesterone AUC by up to 50% in some case reports, risking under-dosing and endometrial breakthrough.
• CNS depressants (benzodiazepines, Z-drugs, opioids): additive sedation. The combination with zolpidem in particular has generated FAERS reports of next-morning impaired driving.
• Anticoagulants (warfarin, apixaban): no pharmacokinetic interaction documented, but VTE risk assessment should be updated before prescribing any hormone therapy.

A full interaction check against the NIH Drug Interaction Database is recommended before initiating Prometrium in any patient on three or more medications.

Managing and Mitigating Prometrium Side Effects

Side effect management follows a step-wise approach tied to severity grade:

Grade 1 (Mild, Not Limiting Daily Function)

Bedtime administration resolves most sedation complaints. A trial period of four to six weeks allows CNS receptor adaptation. Breast tenderness often responds to evening primrose oil 1,000 mg daily (evidence grade: low, but no known safety concerns at this dose). Clinicians should set expectations: most Grade 1 effects resolve by week six.

Grade 2 (Moderate, Affecting Quality of Life)

Consider dose reduction from 200 mg to 100 mg oral nightly. If endometrial protection adequacy is a concern at 100 mg, switch to a hybrid regimen: 100 mg oral plus 4% vaginal gel on alternate nights. A 2013 pharmacokinetic study in Menopause confirmed that vaginal micronized progesterone produces higher endometrial tissue concentrations per plasma unit than oral dosing, the "first-uterine-pass effect," meaning lower systemic doses can achieve equivalent endometrial protection.

For mood-related Grade 2 effects in PMDD-phenotype patients, switching fully to vaginal delivery is preferred over dose reduction.

Grade 3 (Severe, Requiring Discontinuation or Route Change)

Anaphylaxis (peanut allergy): discontinue immediately, administer epinephrine per protocol, do not rechallenge. Permanent switch to a peanut-oil-free preparation is mandatory.

Cholestatic jaundice: discontinue oral Prometrium, check LFTs and direct bilirubin, consult hepatology. Vaginal route may be considered after hepatic normalization with specialist input.

Severe depression with suicidal ideation: discontinue immediately, refer to psychiatry, document adverse event in FAERS if causality is suspected.